AI Protein design, machine learning and cancer care, and pharmaceuticals: At Exazyme, CEO and Co-Founder Ingmar Schuster uses AI to design proteins. He speaks with Jon Krohn about their wider applications in pharmaceuticals and chemistry, how Kernel methods make the design of synthetic biological catalysts more efficient, and when to use shallow machine learning over deep learning.This episode is brought to you by Gurobi, the Decision Intelligence Leader. Interested in sponsoring a SuperDataScience Podcast episode? Visit JonKrohn.com/podcast for sponsorship information.In this episode you will learn:• On designing proteins with AI [03:14]• Designing proteins at Exazyme [08:22]• About the kernel methods [18:10]• The importance of human-led approaches in protein research [35:44]• Europe’s focus on AI regulation [43:45]• Deep vs shallow in AI [59:35]• How a background in academia helps with entrepreneurship [1:09:17]Additional materials: www.superdatascience.com/739

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related